Search the Newsreel

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 11:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Roger SusiChief Financial Officer - John Glenn TAKEAWAYS Revenue -- $20.5 million, representing a 0.5% increase from $20.4 million in the second …

Replacement Cycle Anchors IRadimed Corp.’s (IRMD) Long Term Growth

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

Reaffirmed 2026 Guidance and Dividend Policy Could Be A Game Changer For IRADIMED (IRMD)

iRadimed declares $0.20 dividend

* iRadimed (IRMD [https://seekingalpha.com/symbol/IRMD]) declares $0.20/share quarterly dividend [https://seekingalpha.com/pr/20602837-iradimed-corporation-reports-second-quarter-2026-financial-results], in line with previous. * Forward yield [https://seekingalpha.com/symbol/IRMD/dividends/yield?source=news_bullet] 0.88% * Payable Aug. 28; for shareholders of record Aug. 14; ex-div Aug. 14. * See IRMD Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/IRMD/dividends?source=news_bullet] MORE ON …

IRADIMED (IRMD) Stock Drops As 3870 Ramp Cuts Gross Margin

IRADIMED (IRMD) stock dropped 4.6% despite posting Q2 revenue of US$20.5m and non-GAAP EPS of US$0.46. The company experienced a deliberate hit to its gross margin, which compressed from 78% to 74%, as the new 3870 MR intravenous pump moved into a higher volume …

IRADIMED CORP Q2 2026: Revenue $20.47M, EPS $0.41— 10-Q Summary

IRADIMED CORP reported its second-quarter 2026 results, showing flat revenue year-over-year at $20.47M, while net income and diluted EPS decreased due to margin pressure from new-product production. Revenue growth was driven by device launches and disposables, with a notable shift in geographic mix as …

Earnings call transcript: IRadimed tops Q2 2026 estimates as 3870 ramp weighs margins

IRadimed anticipates Q3 revenue of $23M-$24.5M as 3870 pump production ramps to over 300 units

Earnings Call Insights: IRadimed (IRMD) Q2 2026 MANAGEMENT VIEW * “This quarter, we embarked on the first general release production of the new 3870 MR IV pump system as planned, targeting... the building of 130 to 135 of these new pumps,” and “achieved our …

IRADIMED: More Than 70% of New Pump Orders Were Four-Pump Setups

IRADIMED (NASDAQ: IRMD) announced its Q2 2026 financial results, reporting $20.5 million in revenue, up 0.5% year-over-year, with GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46. The company reaffirmed its full-year 2026 guidance, expecting $91.0–$96.0 million in revenue and GAAP EPS …

IRadimed: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for IRadimed. The content is concise and directly presents the company's performance for the quarter.

Iradimed reports Q2 revenue $20.5M, EPS $0.41; raises dividend to $0.20 and reaffirms 2026 guidance

Iradimed (IRMD) reported Q2 revenue of $20.5 million and diluted EPS of $0.41, alongside declaring a $0.20 quarterly dividend. The company reaffirmed its Q3 and full-year 2026 revenue and GAAP EPS guidance, anticipating revenue between $91.0M–$96.0M and GAAP EPS of $1.90–$2.05 for the full …

iRadimed (NASDAQ:IRMD) Releases Q3 2026 Earnings Guidance

Iradimed Co earnings beat by $0.02, revenue topped estimates

Renaissance Technologies LLC Sells 15,700 Shares of iRadimed Corporation $IRMD

Renaissance Technologies LLC reduced its stake in iRadimed Corporation by 3.4% during the first quarter, selling 15,700 shares but still retaining 440,712 shares valued at approximately $42.4 million. Despite this sale, institutional investors collectively own 92.34% of the company, and analysts maintain a "Buy" …

Iradimed earnings on deck as growth momentum faces Q2 test

Iradimed (IRMD) is set to report its second-quarter earnings, with analysts expecting $0.44 earnings per share on $20.35 million in revenue, a sequential decline from Q1. Investors will focus on the performance of its new MRI-compatible IV infusion pump, margin sustainability, and management's reaffirmation …

Record Results, New MRI Pump And Dividend Hike Might Change The Case For Investing In IRADIMED (IRMD)

IRADIMED (IRMD) recently reported record 2025 results, strong Q1 2026, and FDA clearance for its upgraded MRidium 3870 MRI IV infusion pump, alongside an increased quarterly dividend. These developments, particularly the new pump expected to drive replacement demand, are highlighted as potentially reshaping the …

IRadimed Corp (IRMD) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of IRadimed Corp (IRMD), noting its current financial score is 9.60, ranking it 2nd in the Healthcare Equipment & Supplies industry. It highlights the company's robust financial status and high operating efficiency, with a recent quarterly revenue …

BlackRock (IRMD holder) discloses 5.01% IRADIMED CORP stake on Schedule 13G

BlackRock, Inc. has disclosed a passive ownership stake of 5.01% in IRADIMED CORP (IRMD) common stock, as reported on a Schedule 13G filing. As of June 30, 2026, BlackRock beneficially owned 641,128 shares, with sole voting power over 622,925 shares and sole dispositive power …

Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline

Riverwater Partners, an investment management company, released its "Micro Opportunities Strategy" Q2 2026 investor letter. A copy of the letter is available to download here. In Q2 2026, the Micro Opportunities strategy underperformed the Russell Microcap Index, despite a positive absolute result. The benchmark …

IRMD|IRadimed Corp|Price:94.860|Chg%:+0.370

This article provides a comprehensive stock analysis of IRadimed Corp (IRMD) by TradingKey, highlighting its strong fundamentals, high growth potential, and institutional confidence. The company specializes in MRI-compatible medical devices, with revenue growth averaging 27.84% annually over the last three years and high dividend …

Can IradiMed Extend Its Earnings Momentum In Q2 2026, Will Device Sales Continue To Climb?

(RTTNews) - IRADIMED CORPORATION (IRMD), a medical device company, announced Friday that it will release its results for the second quarter of fiscal 2026 before the market opens on July 31, 2026. The company's management will host a conference call at 11:00 a.m. ET …

IRadimed Corp (IRMD) Stock Price Live, Chart & News - TradingKey

IRadimed Corp (IRMD) is currently trading at $92.495, up 1.41%. The company specializes in MRI-compatible medical devices, including IV infusion pumps and vital signs monitors. Analysts rate IRMD as a "Buy" with a target price of $118.00, indicating a 29.37% upside.

IRadimed Corp (IRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for IRadimed Corp (IRMD), segmenting its revenue by business and by region. The data, updated on April 6, analyzes contributions from MRI-compatible IV infusion pumps, patient vital signs monitoring systems, disposables, extended warranty amortization, and ferro magnetic …

IRadimed Corp (IRMD) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts for IRadimed Corp (IRMD), detailing interim and final cash dividends with their respective record, payment, and ex-dividend dates. Over the past five years, IRadimed Corp has distributed a total of 39.46 million USD in dividends. …

IRadimed Corp (IRMD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of IRadimed Corp (IRMD), outlining major individual and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over time, and notable shareholder activity including changes in positions. The report also lists several ETFs that hold …

IRadimed Corp (IRMD) Cash Flow

This article provides a detailed historical cash flow statement for IRadimed Corp (IRMD), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures for various cash flow components from FY2013Q1 through FY2026Q1, along with year-over-year percentage changes. The report …

IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026

ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Iradimed management will host a conference call the same day …

Before market open, IRADIMED will release Q2 results July 31

IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its Q2 2026 financial results before the market opens on Friday, July 31, 2026. Management will host a conference call at 11:00 a.m. Eastern Time the same day to discuss the results and answer questions. The …

IRADIMED (IRMD) As MRI Pump Upgrade Narrative Points To Fair Value Above The Stock

IRADIMED (IRMD) stock has gained renewed attention, with analysts suggesting an 18% undervaluation and a fair value of $118 per share, largely due to the new 3870 MRI-compatible IV pump. While the upgrade narrative points to future revenue growth and a replacement cycle, the …

Iradimed Corp (IRMD) Q3 2024 Earnings Report - Results, Call & Slides

Iradimed Corp (IRMD) reported its Q3 2024 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of $0.43 against a consensus of $0.41, and actual revenue of $18.33 million against an expected $18.15 million, reflecting an 11.04% year-over-year growth. The …